BP 2015 Annual Report Download - page 90

Deferred shares (audited)a
Deferred share element interests Interests vested in 2015 and 2016
Bonus year Type
Performance
period
Date of award of
deferred shares
Potential maximum deferred shares
Number of
ordinary
shares
vested Vesting date
£
Face value
of the award
At 1 Jan
2015
Awarded
2015
At 31 Dec
2015
Bob Dudleyb2011 Comp 2012-2014 08 Mar 2012 109,206 – – 126,444c 11 Feb 2015 –
Vol 2012-2014 08 Mar 2012 109,206 – – 126,444c 11 Feb 2015 –
Mat 2012-2014 08 Mar 2012 218,412 – – 252,894c 11 Feb 2015 –
2012 Comp 2013-2015 11 Feb 2013 114,690 –114,690 134,856c9 Feb 2016 –
Vol 2013-2015 11 Feb 2013 114,690 –114,690 134,856c9 Feb 2016 –
Mat 2013-2015 11 Feb 2013 229,380 –229,380 269,712c9 Feb 2016 –
2013dComp 2014-2016 12 Feb 2014 149,628 –149,628 – – 728,688
Mat 2014-2016 12 Feb 2014 149,628 –149,628 – – 728,688
2014eComp 2015-2017 11 Feb 2015 –147,054 147,05 4 – – 655,861
Vol 2015-2017 11 Feb 2015 –147,054 147,05 4 – – 655,861
Mat 2015-2017 11 Feb 2015 –29 4,108 294,108 – – 1,311,722
Dr Brian Gilvary 2011 DABf2012-2014 15 Mar 2012 73,624 – – 84,491c 15 Jan 2015 –
2012 Comp 2013-2015 11 Feb 2013 78,815 –78,815 95,226c9 Feb 2016 –
Vol 2013-2015 11 Feb 2013 78,815 –78,815 95,226 c 9 Feb 2016 –
Mat 2013-2015 11 Feb 2013 157,630 –157,630 190,453c9 Feb 2016 –
2013dComp 2014-2016 12 Feb 2014 96,653 –96,653 – – 470,700
Mat 2014-2016 12 Feb 2014 96,653 –96,653 – – 470,700
2014eComp 2015-2017 11 Feb 2015 –88,288 88,288 – – 393,764
Vol 2015-2017 11 Feb 2015 –88,288 88,288 – – 393,764
Mat 2015-2017 11 Feb 2015 –176,576 176,576 – – 787,529
Former executive directors
Iain Conn 2011 Comp 2012-2014 08 Mar 2012 80,652 – – 95,196c 11 Feb 2015 –
Vol 2012-2014 08 Mar 2012 80,652 – – 95,196c 11 Feb 2015 –
Mat 2012-2014 08 Mar 2012 161,304 – – 190,393c 11 Feb 2015 –
2012 Comp 2013-2015 11 Feb 2013 80,648 –80,648 97,441c9 Feb 2016 –
Vol 2013-2015 11 Feb 2013 80,648 –80,648 97,441c9 Feb 2016 –
Mat 2013-2015 11 Feb 2013 107,531g – 107,5 31g 129,922c9 Feb 2016 –
2013dComp 2014-2016 12 Feb 2014 100,563 –100,563 – – 489,742
Mat 2014-2016 12 Feb 2014 33,521g–33,521g– – 163,247
Dr Byron Groteb2011 Comp 2012-2014 08 Mar 2012 91,638 – – 106,104c 11 Feb 2015 –
Vol 2012-2014 08 Mar 2012 91,638 – – 106,104c 11 Feb 2015 –
Mat 2012-2014 08 Mar 2012 91,638g– – 106,104c 11 Feb 2015 –
2012 Comp 2013-2015 11 Feb 2013 97,278 –97,278 114,384c9 Feb 2016 –
Vol 2013-2015 11 Feb 2013 97,278 –97,278 114,384c9 Feb 2016 –
Mat 2013-2015 11 Feb 2013 32,424g–32,424g38,124c9 Feb 2016 –
Comp = Compulsory.
Vol = Voluntary.
Mat = Matching.
DAB = Deferred Annual Bonus Plan.
a Since 2010, vesting of the deferred shares has been subject to a safety and environmental sustainability hurdle, and this will continue. If the committee assesses that there has been a material
deterioration in safety and environmental performance, or there have been major incidents, either of which reveal underlying weaknesses in safety and environmental management, then it may
conclude that shares should vest only in part, or not at all. In reaching its conclusion, the committee will obtain advice from the SEEAC. There is no identified minimum vesting threshold level.
b Bob Dudley and Dr Byron Grote received awards in the form of ADSs. The above numbers reflect calculated equivalents in ordinary shares. One ADS is equivalent to six ordinary shares.
c Represents vestings of shares made at the end of the relevant performance period based on performance achieved under rules of the plan and includes reinvested dividends on the shares vested.
The market price of each share used to determine the total value at vesting on the vesting dates of 15 January 2015, 11 February 2015 and 9 February 2016 were £3.93, £4.46 and £3.34 respectively
and for ADSs on 11 February 2015 and 9 February 2016 were $40.35 and $28.95 respectively.
d The face value has been calculated using the market price of ordinary shares on 12 February 2014 of £4.87.
e The market price at closing of ordinary shares on 11 February 2015 was £4.46 and for ADSs was $40.35. The sterling value has been used to calculate the face value.
f Dr Brian Gilvary was granted the shares under the DAB prior to his appointment as a director. The vesting of these shares is not subject to further performance conditions and he receives deferred
shares at each scrip payment date as part of his election choice.
g All matching shares have been pro-rated to reflect actual service during the performance period and these figures have been used to calculate the face value.
BP Annual Report and Form 20-F 201586